Prima BioMed Ltd (NASDAQ:IMMP) Receives $5.50 Consensus PT from Brokerages

Posted by George Bondi on Sep 24th, 2026

Prima BioMed Ltd (NASDAQ:IMMP – Get Free Report) has been given a consensus rating of “Hold” by the five brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $5.50.

Several research analysts have issued reports on IMMP shares. Jefferies Financial Group upgraded Prima BioMed from a “hold” rating to a “strong-buy” rating in a report on Monday, September 14th. Maxim Group upgraded Prima BioMed from a “hold” rating to a “buy” rating in a report on Wednesday, June 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Prima BioMed in a research report on Friday, July 10th.

Check Out Our Latest Analysis on IMMP

Prima BioMed Trading Down 6.0%

Prima BioMed stock opened at $0.27 on Thursday. Prima BioMed has a 12-month low of $0.26 and a 12-month high of $3.53. The firm’s fifty day moving average is $0.37 and its 200 day moving average is $0.49.

Prima BioMed’s stock is set to reverse split on the morning of Monday, September 28th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, September 27th.

Prima BioMed (NASDAQ:IMMP – Get Free Report) last issued its earnings results on Thursday, July 30th. The biotechnology company reported ($0.09) EPS for the quarter. The firm had revenue of $3.68 million during the quarter.

Prima BioMed Company Profile

(Get Free Report)

Prima BioMed Limited was an Australian biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s research centered on treatments designed to activate or enhance the immune system’s ability to recognize and attack abnormal cells.

Its lead development program was eftilagimod alpha, also known as IMP321, a soluble LAG-3 protein intended to stimulate antigen-presenting cells and support broader immune responses. Prima BioMed evaluated the therapy in combination with existing cancer treatments, including chemotherapy and immune checkpoint inhibitors, across several solid-tumor indications.

The company conducted clinical-development activities internationally, including in Australia, Europe and the United States.